, Columnist
Pharma Tests Preemptive Discounting
Breaking the old pricing model could help launches, but some drugmakers will suffer.
This article is for subscribers only.
Sanofi, Regeneron Pharmaceuticals Inc. and Roche Holding AG are doing something very un-pharma: They're leaving pricing power on the table.
Let's be clear: Sanofi and Regeneron are charging $37,000 a year for their skin-clearing drug Dupixent, and Roche is charging $65,000 a year for its Multiple Sclerosis (MS) drug Ocrevus, both of which the FDA approved earlier this week. That's not exactly chump change.